Doan's Corrective Ads Unrelated To Consumer Misbeliefs - Novartis
This article was originally published in The Tan Sheet
Executive Summary
The Federal Trade Commission failed to prove how ordering Novartis to run $8 mil. in advertising to remedy implied superiority claims for Doan's Pills, including 15-second TV spots containing no corrective statement, would "advance any governmental interest," the company's lawyer charged Feb. 8.
You may also be interested in...
Novartis Doan's Ads Superiority Claims "Material" To Consumers, Court Says
Advertising for Novartis Consumer Health's Doan's Pills as a back pain treatment made implied, deceptive claims of superiority that were material to consumers' purchasing decisions, a federal appeals court says.
Novartis Doan's Ads Superiority Claims "Material" To Consumers, Court Says
Advertising for Novartis Consumer Health's Doan's Pills as a back pain treatment made implied, deceptive claims of superiority that were material to consumers' purchasing decisions, a federal appeals court says.
Novartis Doan's Ads Superiority Claims "Material" To Consumers, Court Says
Advertising for Novartis Consumer Health's Doan's Pills as a back pain treatment made implied, deceptive claims of superiority that were material to consumers' purchasing decisions, a federal appeals court says.